Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.8
5.6
Journals
Biosensors
Special Issues
Biosensing Technologies in Medical Diagnosis—2nd Edition
share announcement

Biosensing Technologies in Medical Diagnosis—2nd Edition

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 5158

Special Issue Editors

Dr. Fei Hu

E-Mail Website
Guest Editor
State Key Laboratory for Manufacturing System Engineering, School of Instrument Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China
Interests: biosensor; nucleic acid; diagnostics
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Niancai Peng

E-Mail Website
Guest Editor
State Key Laboratory for Manufacturing System Engineering, School of Instrument Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China
Interests: biomedical testing technology and instrumentation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are excited to announce the launch of the second volume of our Special Issue, titled “Biosensing Technologies in Medical Diagnosis—2nd Edition”. Building upon the success of our first edition (https://www.mdpi.com/journal/biosensors/special_issues/U67F1RA4V4), this Special Issue aims to further explore the rapidly evolving field of biosensing technologies in medical diagnostics.

As an effective means of obtaining biological information, biosensing is a pioneering and core technology in medical diagnostics. Innovation and application progress in this technology are critical for the development of new diagnostic methods and instruments. Biosensing-based analytical methods, including early and rapid diagnosis, bedside supervision, and in vivo monitoring, provide important guidance for immediate and precision medical care.

This Special Issue focuses on the innovative advances and applications of biosensing technologies in medical diagnostics. The Issue invites manuscripts (research papers, perspectives, and review articles) related to biosensing applications including, but not limited to, bioassay, bioseparation, point-of-care tests, gene engineering, cell analysis, drug screening, tissue engineering, regenerative medicine, personalized healthcare, etc. Articles regarding the integration of advanced diagnostic techniques and testing devices are also encouraged to be submitted. We look forward to receiving your contributions and sharing the latest advances in the application of biosensing technologies in medical diagnosis with our readers.

Dr. Fei Hu
Prof. Dr. Niancai Peng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostics
  • biodetection
  • biosensors
  • bioseparation
  • biomaterial
  • genomics
  • nucleic acid detection
  • immunoassay
  • wearable medical testing
  • microfluidics and its application to medical testing
  • cell analysis
  • point-of-care testing
  • drug screening
  • tissue engineering
  • regenerative medicine
  • personalized healthcare

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 21989 KB  
Article
Imaging Study of MnO2-Based Nanomotors Modulating HIF-1α/Lipid Droplet Biogenesis and Activating the cGAS-STING Pathway
by Ziyi Li, Yingxin Tian, Gefei Ren and Yingshu Guo
Biosensors 2026, 16(5), 261; https://doi.org/10.3390/bios16050261 - 1 May 2026
Viewed by 813
Abstract
The overexpression of hypoxia-inducible factor-1α (HIF-1α) suppresses STING signaling and modulates lipid metabolism in tumor cells, leading to abnormal lipid droplet (LD) accumulation. Herein, we constructed a manganese dioxide (MnO2)-based nanomotor (HMIP@A). HMIP@A depletes intracellular hydrogen peroxide (H2O2 [...] Read more.
The overexpression of hypoxia-inducible factor-1α (HIF-1α) suppresses STING signaling and modulates lipid metabolism in tumor cells, leading to abnormal lipid droplet (LD) accumulation. Herein, we constructed a manganese dioxide (MnO2)-based nanomotor (HMIP@A). HMIP@A depletes intracellular hydrogen peroxide (H2O2) and glutathione (GSH) to generate oxygen (O2), reactive oxygen species (ROS), and manganese (Mn2+). A dual strategy of “oxygen supplementation” and “small-molecule inhibition” synergistically downregulates HIF-1α, thereby suppressing LD biogenesis. This process sensitizes tumor cells to ROS, leading to severe DNA damage. Released Mn2+ and damaged DNA synergistically activate the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway. In vitro, HMIP@A markedly increases ROS production, lipid peroxidation (LPO), and DNA damage, thereby inducing tumor cell death, immunogenic cell death (ICD), and dendritic cell (DC) maturation. Furthermore, HMIP@A exhibits excellent penetration in tumor spheroids. Overall, this study provides a theoretical basis for the design of nanomedicines through a strategy integrating metabolic intervention, oxidative damage sensitization, and immune activation. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis—2nd Edition)
►▼ Show Figures

Figure 1

14 pages, 1291 KB  
Article
Integrated Microfluidic Giant Magnetoresistance (GMR) Biosensor Platform for Magnetoresistive Immunoassay of Myoglobin
by Yikai Wang, Huaiyu Wang, Yunyun Zhang, Shuhui Cui, Fei Hu and Bo’an Li
Biosensors 2026, 16(1), 8; https://doi.org/10.3390/bios16010008 - 22 Dec 2025
Cited by 1 | Viewed by 1916
Abstract
Acute myocardial infarction (AMI) is a rapidly progressing cardiovascular condition associated with high mortality. Myoglobin is an early biomarker of AMI; however, its detection using conventional methods is limited by complex workflows and low resistance to interference. In this study, we developed an [...] Read more.
Acute myocardial infarction (AMI) is a rapidly progressing cardiovascular condition associated with high mortality. Myoglobin is an early biomarker of AMI; however, its detection using conventional methods is limited by complex workflows and low resistance to interference. In this study, we developed an integrated myoglobin detection platform that combined magneto-immunoassay with microfluidic technology. A giant magnetoresistance (GMR) sensor was fabricated using micro-electro-mechanical systems (MEMS). The designed microfluidic chip integrated sample pretreatment, immunoreaction, and magnetic signal capture functionalities. Its built-in GMR sensor, labeled with magnetic nanoparticles, directly converted the “antigen–antibody” biochemical signal into detectable magnetoresistance changes, thereby enabling the indirect detection of myoglobin. A magneto-immunoassay analysis system consisted of a fluidic drive, magnetic field control, and data acquisition functions. Various key parameters were optimized, including EDC/NHS concentration, antibody concentration, and magnetic bead size. Under the optimal conditions and using 1 μm magnetic beads as labels and an external detection magnetic field of 60 Oe, the platform successfully detected myoglobin at 75 ng/mL with ∆MR ≥ 0.202%. Specificity tests demonstrated that the platform had high specificity for myoglobin and could effectively distinguish myoglobin from bovine serum albumin (BSA) and troponin I. This study presents a rapid, accurate myoglobin detection platform that can be applied for the early diagnosis of AMI. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis—2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 1467 KB  
Review
State-of-the-Art and Next Generation Intra-Articular Implantable Biosensors for Osteoarthritis: From Analytical Limits to Operational Stability
by Abdullateef Gbolahan Olayiwola, Albina Abdossova, Daniele Tosi, Gorka Orive, Zhe Liu and Cevat Erisken
Biosensors 2026, 16(5), 283; https://doi.org/10.3390/bios16050283 - 14 May 2026
Viewed by 262
Abstract
Osteoarthritis (OA) and osteochondral degeneration present a significant clinical burden characterized by the complex interplay of extracellular matrix degradation and chronic inflammation. While biochemical profiling has matured, a critical translational gap remains in transitioning from benchtop assays to systems capable of continuous, intra-articular [...] Read more.
Osteoarthritis (OA) and osteochondral degeneration present a significant clinical burden characterized by the complex interplay of extracellular matrix degradation and chronic inflammation. While biochemical profiling has matured, a critical translational gap remains in transitioning from benchtop assays to systems capable of continuous, intra-articular monitoring. This review provides a comprehensive synthesis of experimentally validated biosensing technologies, including optical, electrochemical, and piezoelectric Quartz Crystal Microbalance (QCM) platforms, evaluated through the lens of sensing architecture, biomarker specificity, and matrix compatibility. Our analysis reveals that while optical sensors offer superior sensitivity, electrochemical platforms show the greatest promise for miniaturized, implantable integration. However, a pivot in the field is identified: the primary bottleneck has shifted from analytical detection limits to operational stability within the hostile synovial environment. Current research is largely restricted to single-analyte detection in simplified media, failing to address the multifactorial nature of OA. We propose that the next generation of osteochondral diagnostics must prioritize multiplexed arrays, mechanically compliant architectures, and machine-learning-assisted signal processing. By bridging these engineering frontiers, biosensors will evolve from passive diagnostic tools into intelligent, personalized platforms for real-time disease management. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis—2nd Edition)
►▼ Show Figures

Figure 1

35 pages, 3387 KB  
Review
Immunosensing Platforms for Detection of Metabolic Biomarkers in Oral Fluids
by Nadezhda S. Komova, Kseniya V. Serebrennikova, Anatoly V. Zherdev and Boris B. Dzantiev
Biosensors 2025, 15(12), 794; https://doi.org/10.3390/bios15120794 - 2 Dec 2025
Viewed by 1736
Abstract
Widespread and simple detection of diseases and disfunctions in the body is crucial for reliable and prompt diagnostics, efficient use of healthcare resources, and improved quality of life. The presence of a large number of metabolic products in saliva, the relationship between their [...] Read more.
Widespread and simple detection of diseases and disfunctions in the body is crucial for reliable and prompt diagnostics, efficient use of healthcare resources, and improved quality of life. The presence of a large number of metabolic products in saliva, the relationship between their levels in saliva and blood, the diagnostic value of many of these compounds, and the advantages of noninvasive sampling drive interest in oral fluid as a biomatrix. This review summarizes established oral fluid biomarkers, as well as potential salivary indicators for remote health monitoring and noninvasive point-of-care diagnostics. Recent advances in the search for new solutions for sensitive and high-throughput immunodetection of biomarkers in oral fluid are discussed, along with strategies for overcoming the analytical and technical challenges associated with the salivary matrix testing. Another focus of the current review is optical and electrochemical immunosensors with an emphasis on lateral flow immunoassays for point-of-care testing due to their speed, simplicity and cost-effectiveness. Finally, future directions are discussed that may enable non-invasive monitoring of endocrine, infectious, immune, neurodegenerative diseases and other human conditions using immunoassay platforms, paving the way for personalized and accessible healthcare. Full article
(This article belongs to the Special Issue Biosensing Technologies in Medical Diagnosis—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop